MONTRÉAL, July 08, 2025 (GLOBE NEWSWIRE) -- D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO), a global leader in immersive motion experiences across movie theatres, sim racing, gaming, and simulation training, today announced that Jean-François Gagnon, Senior Vice President, will be stepping down from his role effective August 15, 2025. Following his departure, the sales and marketing teams will report directly to Naveen Prasad, Interim Chief Executive Officer for the time being. This trans ...

Etching out fresh 52-week highs in the past few trading sessions, SoFi Technologies (SOFI)  stock has been a standout among the financial sector. As a member-centric, one-stop shop for financial services, SoFi is benefiting from several positive catalysts that have lifted investor sentiment.   Sitting on +30% gains in 2025, SoFi stock has now soared over +200% in the last three years, hitting another 52-week high of $20 a share on Tuesday.Edging closer to an all-time peak of $25 a share, let’s see if SoFi s ...

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All o ...

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner Figure 1- SCI motor function after different doses of ExoPTEN (A) Paw use detected by the CatWalk XT camera.(B-F) CatWalk XT gait analysis demonstrates dose-dependent functional improvement following ExoPTEN treatment:B – % of hindlimbs recorded by CatWalk XT gait analysis system, recording of prints by CatWalk XT requires minimal use of leg and weight support, improvement can be seen in a dose dependen ...

RADNOR, Pa., July 8, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Sarepta losses, ...

CARLSBAD, Calif., July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.Details of the poster presentation are below: Title: "TYR ...

Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.e ...

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - - Expands Solid’s clinical pipeline to include first cardiac indication with urgent unmet medical need - CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SL ...

Key Takeaways Yext, Agenus and NCR Voyix are exhibiting strong earnings acceleration across recent quarters. YEXT, AGEN and VYX all have projected EPS growth rates exceeding prior quarterly growth trends. VYX leads with 152.7% expected EPS growth, followed by AGEN at 114.7% and YEXT at 37.1% this year.Senior executives and financial analysts focus on steady earnings growth, as this indicates a company’s profitability. However, a rapid rise in earnings can have an even greater effect in driving stock price ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...